Bone marrow WT1 levels at diagnosis, post-induction and post-intensification in adult de novo AML
Por:
Nomdedeu, JF, Hoyos, M, Carricondo, M, Bussaglia, E, Estivill, C, Esteve, J, Tormo, M, Duarte, R, Salamero, O, de Llano, MPQ, Garcia, A, Bargay, J, Heras, I, Marti-Tutusaus, JM, Llorente, A, Ribera, JM, Gallardo, D, Aventin, A, Brunet, S, Sierra, J
Publicada:
1 nov 2013
Resumen:
We retrospectively assessed whether normalized bone marrow WT1 levels could be used for risk stratification in a consecutive series of 584 acute myeloid leukemia (AML) patients. A cutoff value of 5065 copies at diagnosis identified two prognostic groups (overall survival (OS): 44 +/- 3 vs 36 +/- 3%, P = 0.023; leukemia-free survival (LFS): 47 +/- 3 vs 36 +/- 4%, P = 0.038; and cumulative incidence of relapse (CIR): 37 +/- 3 vs 47 +/- 4%, P = 0.043). Three groups were identified on the basis of WT1 levels post-induction: Group 0 (WT1 between 0 and 17.5 copies, 134 patients, OS: 59 +/- 4%, LFS: 59 +/- 4% and CIR: 26 +/- 4%); Group 1 (WT1 between 17.6 and 170.5 copies, 160 patients, OS: 48 +/- 5%, LFS: 41 +/- 4% and CIR: 45 +/- 4%); and Group 2 (WT1 > 170.5 copies, 71 patients, OS: 23 +/- 6%, LFS: 19 +/- 7% and CIR: 68 +/- 8%) (P<0.001). Post-intensification samples distinguished three groups: patients with WT1 > 100 copies (47 patients, 16%); an intermediate group of patients with WT1 between 10 and 100 copies (148 patients, 52%); and a third group with WT1 o10 copies (92 patients, 32%). Outcomes differed significantly in terms of OS (30 +/- 7%, 59 +/- 4%, 72 +/- 5%), LFS (24 +/- 7%, 46 +/- 4%, 65 +/- 5%) and relapse probability (CIR 72 +/- 7%, 45 +/- 4%, 25 +/- 5%), all P<0.001. WT1 levels in bone marrow assayed using the standardized ELN method provide relevant prognostic information in de novo AML.
Filiaciones:
Nomdedeu, JF:
Univ Autonoma Barcelona, Hosp Santa Creu & St Pau, Lab Hematol, Barcelona 08041, Spain
Hoyos, M:
Univ Barcelona, Barcelona, Spain
Hosp Santa Creu & Sant Pau, Hematol Dept, Barcelona, Spain
Carricondo, M:
Univ Autonoma Barcelona, Hosp Santa Creu & St Pau, Lab Hematol, Barcelona 08041, Spain
Bussaglia, E:
Univ Autonoma Barcelona, Hosp Santa Creu & St Pau, Lab Hematol, Barcelona 08041, Spain
Estivill, C:
Univ Autonoma Barcelona, Hosp Santa Creu & St Pau, Lab Hematol, Barcelona 08041, Spain
Esteve, J:
Hosp Clin Barcelona, Hematol Dept, Barcelona, Spain
Tormo, M:
Hosp Clin, Hematol Dept, Valencia, Spain
Duarte, R:
ICO Hosp, Hematol Dept, Lhospitalet De Llobregat, Spain
Salamero, O:
Hosp Valle De Hebron, Hematol Dept, Barcelona, Spain
de Llano, MPQ:
Hosp Virgen Victoria, Hematol Dept, Malaga, Spain
Garcia, A:
Hosp Arnau Vilanova, Hematol Dept, Lleida, Spain
Bargay, J:
Hosp Son Llatzer, Hematol Dept, Palma De Mallorca, Spain
Heras, I:
Hosp Morales Meseguer, Hematol Dept, Murcia, Spain
Marti-Tutusaus, JM:
Hosp Mutua Terrassa, Dept Hematol, Terrassa, Spain
Llorente, A:
Hosp Joan 23, Dept Hematol, Tarragona, Spain
Ribera, JM:
ICO Badalona, Dept Hematol, Badalona, Spain
Gallardo, D:
ICO Girona, Dept Hematol, Girona, Spain
Aventin, A:
Univ Autonoma Barcelona, Hosp Santa Creu & St Pau, Lab Hematol, Barcelona 08041, Spain
Brunet, S:
Hosp Santa Creu & Sant Pau, Hematol Dept, Barcelona, Spain
Sierra, J:
Hosp Santa Creu & Sant Pau, Hematol Dept, Barcelona, Spain
Bronze
|